Constellation Pharmaceuticals, Inc.
CNST
CNST was delisted on the 14th of July, 2021.
99 hedge funds and large institutions have $1.23B invested in Constellation Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 25 reducing their positions, and 21 closing their positions.
290% more call options, than puts
Call options by funds: $1.98M | Put options by funds: $509K
72% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 25
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
2.04% more ownership
Funds ownership: 91.24% → 93.28% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 12 → 12 (0)
1% less funds holding
Funds holding: 100 → 99 (-1)
32% less capital invested
Capital invested by funds: $1.8B → $1.23B (-$570M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$35.7M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$29.3M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$22.7M |
| 4 |
DM
Deerfield Management
New York
|
+$14M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TG
TRV GP
Boston,
Massachusetts
|
-$52.1M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$21.6M |
| 3 |
Jennison Associates
New York
|
-$11.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$9.57M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.04M |
CNST Hedge Fund Activity: Q1 2020 in Review
99 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q1 2020, worth a combined $1.23B — down 32% from $1.8B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CNST positions and 21 closed out — a net gain of 3 holders — while 43 added to existing stakes and 25 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $35.7M. The largest seller was TRV GP, cutting an estimated $52.1M.
- 99 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q1 2020, down from 100 in Q4 2019.
- Funds reported $1.23B of Constellation Pharmaceuticals, Inc. stock for Q1 2020, down 32% quarter-over-quarter.
- 24 funds opened new Constellation Pharmaceuticals, Inc. positions in Q1 2020 and 21 closed out, a net change of +3 holders.
- The largest Constellation Pharmaceuticals, Inc. buyer in Q1 2020 was Point72 Asset Management, an estimated $35.7M added.
- The largest Constellation Pharmaceuticals, Inc. seller in Q1 2020 was TRV GP, an estimated $52.1M sold.
Based on aggregated 13F filings for Q1 2020.